Tifcemalimab is named as an intervention in 7 current clinical trials in our China, Spain, Netherlands, Turkey, Taiwan and Israel registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai Junshi Bioscience Co., Ltd (3). The most-studied condition is Hodgkin Lymphoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Junshi Bioscience Co., Ltd | 3 |
| Shanghai Pulmonary Hospital, Shanghai, China | 2 |
| Fudan University | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 7 | 5 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Turkey | 1 | 1 |
| Clinical trials in Taiwan | 1 | 1 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our China, Spain, Netherlands, Turkey, Taiwan and Israel registers name Tifcemalimab (also registered as JS004) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 7 trials are recruiting: 5 with sites in China, 1 with sites in Spain, 1 with sites in Netherlands, 1 with sites in Turkey, 1 with sites in Taiwan and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Junshi Bioscience Co., Ltd (3), Shanghai Pulmonary Hospital, Shanghai, China (2) and Fudan University (2). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tifcemalimab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tifcemalimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tifcemalimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.